DPP4 inhibitors
DPP4 Inhibitors
DPP4 inhibitors or Dipeptidyl peptidase-4 inhibitors (pronunciation: /diːpeptɪdaɪl peɪptɪdeɪs-4 ɪnˈhɪbɪtərs/) are a class of medicine used primarily to treat Type 2 diabetes.
Etymology
The term "DPP4 inhibitors" is derived from the name of the enzyme they inhibit, Dipeptidyl peptidase-4. The word "inhibitor" comes from the Latin word 'inhibere', meaning 'to hold back', referring to the function of these drugs to inhibit or reduce the activity of the DPP4 enzyme.
Function
DPP4 inhibitors work by blocking the action of DPP4, an enzyme which destroys the hormone GLP-1 (Glucagon-like peptide-1). GLP-1 is an important hormone that helps regulate blood sugar levels. By inhibiting DPP4, these drugs increase the levels of GLP-1, thereby helping to control blood glucose levels.
Related Terms
- Type 2 diabetes: A chronic condition that affects the way the body processes blood sugar (glucose).
- GLP-1: A hormone that helps regulate blood sugar levels.
- Enzyme: A substance produced by a living organism which acts as a catalyst to bring about a specific biochemical reaction.
- Blood glucose levels: The amount of glucose present in the blood.
Examples
Some examples of DPP4 inhibitors include Sitagliptin, Saxagliptin, and Linagliptin. These are all oral medications that are used in conjunction with diet and exercise to improve blood sugar control in adults with type 2 diabetes.
External links
- Medical encyclopedia article on DPP4 inhibitors
- Wikipedia's article - DPP4 inhibitors
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski